Background: Despite the importance of inflammation in cancer, the role of the cytokine IL-33, and its receptor ST2, in colon cancer is unclear. The aim of this study was to investigate the role of IL-33, and its receptor isoforms (ST2 and ST2L), in colon cancer.
Interleukin (IL)-33 is a member of the IL-1 superfamily, identified in 2005 as the ligand for the receptor ST2. Differential mRNA processing within the ST2 gene generates three isoforms of ST2 proteins: a transmembrane receptor (ST2L), a secreted soluble form (sST2) and a variant form (ST2V; Garlanda et al, 2013) . Initial studies on the role of ST2L in the immune system demonstrated that ST2L is expressed on many immune cells, including macrophages, mast cells, innate lymphoid cells and T cells, in particular Th2 cells . Moreover, signalling through ST2L promotes the development of Th2 cells, and the induction of the Th2 cytokines IL-4, IL-5 and IL-13. sST2 is thought to act as a decoy receptor, binding to IL-33, whereas the function of ST2V is unclear. More recently, research on IL-33/ST2 has predominantly focused on their role in chronic disorders, with IL-33 and ST2 involved a role in the pathogenesis of several human inflammatory diseases including inflammatory bowel disease (Pastorelli et al, 2010; Sedhom et al, 2013) .
Given the importance of inflammation in cancer, recent studies have begun to investigate the role of IL-33 and ST2 in carcinogenesis. Interleukin-33 has been shown to be elevated in the serum of patients with cancer, including that of gastric, lung and hepatocellular cancer patients (Chen et al, 2014) , with high levels of sST2 detected in the serum of metastatic breast cancer (Gillibert-Duplantier et al, 2012) and hepatocellular cancer patients (Bergis et al, 2013) . Studies in breast cancer have suggested that the IL-33/ST2 pathway inhibits antitumour immunity, subsequently promoting breast cancer metastasis (Jovanovic et al, 2014) . Other studies have implicated a role for IL-33 and ST2 in tumour cell invasion and metastasis, with inhibition of IL-33 in glioma cells and colon cancer cells resulting in reduced tumour growth, migration and colony formation in vitro, and smaller tumours in vivo (Fang et al, 2014; Liu et al, 2014) . Interleukin-33 was also shown to activate tumour stroma and promote polyposis in APC (Min/ þ ) mice (Maywald et al, 2015) . In contrast, a protective role for IL-33 has been reported in other studies, with IL-33 reduced in the plasma of non-small-cell lung cancer relative to controls (Barrera et al, 2015) , and IL-33 negatively correlating with the tumour stage in multiple myeloma patients (Musolino et al, 2013) . Moreover, whereas expression of both IL-33 and ST2 was shown to be increased in intestinal adenomas, expression of both proteins was reduced in colorectal carcinomas (Cui et al, 2015) . Moreover, overexpression of IL-33 in tumours resulted in an increase in the antitumour immune response and tumour rejection through the activation of CD8 þ T cells and natural killer (NK) cells (Gao et al, 2015) . Most studies to date, however, have focused predominantly on the role of IL-33 in cancer, with less known about the role of the receptor. Here we demonstrate that suppression of ST2 expression by colon tumour cells results in increased tumour growth in vivo, with progressively lower expression of ST2L by tumour cells observed with increasing tumour stage.
MATERIALS AND METHODS
Study populations. The study protocol, including all procedures and study populations, was approved by the University College Cork Clinical Research Ethics Committee of the Cork Teaching Hospitals (ECM (3) P 3 September 2013). For patient cohort 1, 24 fresh samples of human colon cancer and paired normal tissues were obtained during surgery at the Mercy University Hospital Cork. A blood sample was obtained from each patient before surgery for serum analysis. All samples were collected with patients' informed consent. For patient cohort 2, 68 paraffinembedded formalin-fixed samples were obtained from the archives of Cork University Hospital. Relevant patient history was also extracted from the archives. Control serum samples were obtained from healthy volunteers aged between 18 and 65 years. Patient demographics are contained in Supplementary Table 1. Reagents. Recombinant TNFa was obtained from PeproTech (Rocky Hill, NJ, USA), EGF was purchased from Biolegend Inc (San Diego, CA, USA) and PGE 2 was obtained from Cayman Company (Ann Arbor, MI, USA). LPS was purchased from Invivogen (San Diego, CA, USA). Recombinant IL-33 was obtained from ProSpec (East Brunswick, NJ, USA). The primary antibodies used were as follows: polyclonal anti-human anti-ST2L antibody (cat # NBP1-85251) Novus, (Littleton, CO, USA), anti-mouse anti-ST2 antibody (cat#ab25877) Abcam (Cambridge, UK), anti-human anti-IL-33 antibody (Nessy-1) (cat#ALX-804-840) Enzo Life Sciences (Farmingdale, NY, USA). APC/Cy7 anti-mouse Ly-6G/ Ly-6C antibody and PE anti-mouse F4/80 antibody were obtained from Biolegend Inc. FITC rat anti-mouse CD8 was purchased from BD Biosciences (Franklin Lakes, NJ, USA).
Mice and tumour model. Female BALB/c mice (4-6 weeks) were obtained from Harlan UK (Oxon, UK) and experiments performed in accordance with the institutional guidelines using an Animal Experimentation Ethics Committee-approved protocol (approval 2012/051). To establish subcutaneous tumours, mice were injected into the right flank with 4.0 Â 10 4 CT26 cells resuspended in 200 ml phosphate-buffered saline (five mice per group). Tumour growth was monitored by regular measurement of tumour length (a) and width (b) using a Vernier calliper, and the volume was calculated as follows: ½ Â (a Â b 2 ). Animals were killed 20 or 24 days later and tumours excised. The acceptable maximum tumour volume for mice to be killed was 2 cm 3 , in accordance with the ethical guidelines.
Generation of ST2
Low/negative CT26 cells. Cells were transfected with lentiviral particles containing target-specific shRNAs against ST2 (sc-40036-V) or control lentiviral particles containing scrambled shRNA (sc-108080; Santa Cruz Biotechnology, Dallas, TX, USA), according to the manufacturers' instructions. Puromycin-resistant clones were selected by limiting dilution.
Quantitative real-time PCR. Total RNA was isolated using the GenElute Mammalian Total RNA Mini kit (Sigma-Aldrich, Dorset, UK) according to the manufacturer's instructions, and cDNA was synthesised. Individual PCR primer pairs (Supplementary Table 2 ) and probes were designed using the Roche Universal Probe Library Assay Design Centre. The 2 À DDCT method was used to calculate relative changes in the gene expression.
Immunohistochemistry. Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded (FFPE) sections as previously described (Fernandes et al, 2015) . A semiquantitative scoring system was developed, with each tumour given a score according to the intensity of staining.
Proliferation assay. Cell proliferation was determined by analysing BrdU incorporation into newly synthesised DNA using a Cell Proliferation ELISA System (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions.
Flow cytometry. Single-cell suspensions were prepared by collagenase/dispase digestion. Overall, 200 000 cells were re-suspended in 200 ml of cell-staining buffer, incubated with antibodies to LY6G, CD8 or F4/80 for 30 min at 4 1C in the dark, and then fixed in 1% paraformaldehyde. Relative fluorescence intensities were measured using a FACSLSRII 5 laser (UV/violet/blue/ yellowgreen/red) cytometer and BD Diva software (Becton Dickinson, Oxford, UK). For each sample, 20 000 events were recorded. Dead cells were gated out of the analysis by staining with the viability dye VIVID (Invitrogen). The percentage of cells labelled with each antibody was calculated in comparison with cells stained with isotype control antibody. Analysis gates for each antibody were set by using fluorescence minus one controls with a threshold below 1% (Supplementary Figure 3) . Statistical analysis. Experiments were performed a minimum of three times in triplicate. Results were statistically evaluated using one-way ANOVA with Dunnetts post test, or by Student's paired t-test. The Kendall tau-b correlation coefficient was used to evaluate the association between ST2L expression and tumour stage. Kaplan-Meier analysis was used to calculate survival rates, and differences in survival curves were determined by the log-rank test.
RESULTS
Expression of ST2L in CRC is lower compared with adjacent non-tumour tissue, with expression being progressively lower with higher tumour grade. In order to examine potential alterations in expression of both IL-33 and its receptor ST2 in colorectal cancer stage (CRC), a cohort of 24 patients with CRC was recruited, 8 of whom had received chemotherapy before surgery. Initially, expression levels of IL-33 and ST2 were examined using quantitative real-time PCR (qRT-PCR). There was no change in the level of transcription of either IL-33 or total ST2 between CRC and adjacent non-tumour tissue ( Figure 1A ). We subsequently designed and utilised a primer specific to the intracellular portion of ST2 to examine changes in expression of ST2L in colon cancer. The level of ST2L mRNA was significantly lower (P ¼ 0.0067) in CRC tissue as compared with adjacent nontumour tissue ( Figure 1A ). Alterations in expression were confirmed at the protein level using immunohistochemistry (IHC). No change was observed in either IL-33 or total ST2, although staining intensity for ST2L was consistently lower in CRC as compared to adjacent non-tumour tissue. Representative images are shown in Figure 1B . Serum levels of IL-33 and sST2 were also examined in CRC patients (n ¼ 24) compared with healthy volunteers (n ¼ 15), with a slight decrease in IL-33 (P ¼ 0.0252) and no alterations of sST2 ( Figure 1C ) observed.
We subsequently wished to identify whether there was any association between expression of ST2L and tumour grade. To investigate this, IHC for ST2L was performed on 68 FFPE tissue sections of various stages of CRC, 17 of whom had received chemotherapy. A scoring system was developed, with the staining intensity of ST2L categorised as negative, weak, moderate or strong. As the tumour stage increased, the intensity of ST2L expression observed was lower, with expression of ST2L negatively correlating with tumour grade (Kendall tau-b: À 0.248, P ¼ 0.026). Fifty-seven per cent of stage I tumours showed moderate to strong expression, with only 15% of stage IV tumours showing moderate/ strong expression (Table 1) . Representative images of the ST2L staining obtained for each stage are shown in Figure 2A .
The relationship between the expression levels of ST2L and clinical prognosis in cohort 2 was also assessed. Clinicopathological correlation for these patients was evaluated by determining the patients' survival and clinical progression. There was a trend towards improved overall survival when tumours had strong to moderate expression of ST2L, although this was not statistically significant (P ¼ 0.0838; Figure 2B ).
No association was observed between ST2L expression and chemotherapy treatment. Approximately half of the samples derived from patients receiving chemotherapy were negative for ST2L (9 out of 17) and (5 out of 8), with the remainder all expressing ST2L of varying intensities.
Colon cancer cell lines express ST2L and IL-33, with IL-33 stimulation not increasing cell proliferation or invasion, but inducing migration in vitro. To further characterise and examine the role of ST2 and IL-33 in colon cancer, expression of both ST2L and IL-33 was examined in several colon cancer cell lines. Basal expression of ST2L was low in all three cell lines examined, with expression increased upon stimulation with the pro-inflammatory stimuli, LPS, TNFa and PGE 2 ( Figure 3A ). Interleukin-33 protein was also detected in all cell lines, with no change in expression seen upon stimulation with any of the pro-inflammatory cytokines investigated ( Figure 3A) . In contrast, IL-33 was expressed at a very low basal level in both B16F10 melanoma and A549 lung cancer cells, with expression induced upon stimulation with LPS. Moreover, these cells had high basal levels of ST2L, which was unaltered by either LPS or TNFa (Supplementary Figure 1) . H e a l t h y P a t i e n t s H e a l t h y P a t i e n t s Colon cancer cells were stimulated with increasing concentrations of IL-33 and changes in proliferation and migration examined. Interleukin-33 treatment resulted in a slight decrease in cellular proliferation ( Figure 3B ). In contrast, IL-33 increased the migration of the cells over the levels observed towards 10% serum. This increase in migration occurred in a dose-dependent manner for all cell lines ( Figure 3C ). Interleukin-33, however, had no effect on cell invasion ( Figure 3D ).
Interleukin-33 induces limited expression of cytokines/ chemokines in colon cancer cells. As we had observed expression of ST2L in unstimulated cells, we next investigated whether IL-33 induced the transcription of cytokines, chemokines or angiogenic factors. Stimulation of HT29 ( Figure 4A ) and SW480 ( Figure 4B ) human colon cancer cells with IL-33 had no effect on transcription of a panel of factors, with the exception of CCL2, which was strongly induced in both cell lines. In contrast to the human cell lines, stimulation of murine CT26 cells with IL-33 induced an increase in VEGF, CXCL-1 and CCL2 ( Figure 4C ).
Suppression of ST2 expression in colon cancer cells results in increased tumour growth in vivo. We next investigated the biological effect of reducing ST2 expression in colon cancer cells in a murine model. ST2 expression was reduced in CT26 mouse colon cancer cells using shRNA, the suppression of ST2 being confirmed using western blot analysis ( Figure 5A ). Suppression of ST2 did not affect either the basal level of proliferation ( Figure 5B ), proliferation induced by pro-inflammatory stimuli ( Supplementary  Figure 2A) or migration ( Figure 5C ) of these cells. Consistent with reduced expression of ST2, CT26 ST2 shRNA#1 and #2 cells
showed markedly reduced transcription of CXCL-1 following IL-33 stimulation ( Figure 5D ). Immunocompetent BALB/c mice were injected subcutaneously with CT26 scr shRNA#1 , CT26 ST2 shRNA#1 or CT26 ST2 shRNA#2 cells, and tumour growth monitored. All mice developed palpable tumours. However, in contrast to the in vitro findings, whereby suppression of ST2 did not alter cellular proliferation, tumour growth was increased when ST2 was suppressed in advance by shRNA ( Figure 5E ; Po0.05).
These findings were confirmed in a second independent study using additional CT26 scr shRNA#2 and CT26 ST2 shRNA#3 clones that were subsequently derived. In this second study, the increase in tumour growth following suppression of ST2 was even more pronounced (P ¼ 0.0045; Supplementary Figure 2B-D) .
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Tumours were excised and immune cells analysed using flow cytometry. Although suppression of ST2 in tumours did not affect neutrophil infiltration (Figure 5F ), there was a reduction in macrophage recruitment following ST2 knockdown in the tumour cells ( Figure 5G ). Although not significant, there was also a decrease in the recruitment of CD8 þ T cells ( Figure 5H ). Representative dot plots for the flow cytometric analysis are shown in Supplementary Figure 3. IL-33 induces the recruitment of macrophages in vitro, with IL-33 expression reduced in CT26
ST2shRNA -derived tumours in vivo. It is well established that, if appropriately activated, macrophages can mediate tumour rejection (Edin et al, 2013) . Given the reduction seen in macrophage infiltration in tumours derived from CT26 ST2 shRNA#1 and #2 cells, we investigated whether there was an increase in macrophage migration towards supernatant from IL-33-stimulated tumour cells, relative to untreated tumour cell supernatant. There was an B25% increase in migration of macrophages as compared with unstimulated CT26 cell supernatant ( Figure 6A ). Consistent with the induction of CCL2 by IL-33, a blocking antibody to CCL2 reduced macrophage migration towards the supernatant of IL-33-stimulated CT26 cells (Po0.05; Figure 6A ).
We finally examined expression of IL-33 within the murine tumours. A marked reduction was observed in IL-33 expression within the CT26 ST2 shRNA tumours as compared with CT26 Scr shRNA tumours. Although the underlying mechanism for this reduction in IL-33 in vivo is unclear, it may be due to a lack of positive regulation of IL-33 by ST2L signalling. In conclusion, these data suggest that the alterations in tumour growth in vivo following suppression of ST2 is likely due, at least in part, to a reduction in tumour-expressed IL-33, perhaps due to a reduction in tumourderived macrophage chemotactic factors, and consequent reduction in macrophage recruitment.
DISCUSSION
In this study we have demonstrated, using both a preclinical in vivo model of tumour development involving ectopically injected colon carcinoma cells, as well as human clinical samples, that signalling through ST2 on tumour cells likely has an antitumorigenic role in CRC. We have shown that suppressing ST2 expression in colon tumour cell lines increased tumour growth in vivo. Expression of ST2L was found to be lower in human tumours relative to adjacent non-tumour tissue, with the higher the tumour grade, the lower the expression of ST2L.
Several recent reports have demonstrated an antitumorigenic role for the IL-33-ST2 axis. In these studies, IL-33 was shown to promote the function of CD8 þ T cells and NK cells, thereby promoting tumour eradication (Yang et al, 2011) . Consistent with this, studies examining T-cell infiltration in CRC have shown that high levels of CD8 þ T-cell infiltration is associated with improved overall patient survival (Naito et al, 1998) . Macrophages can also act as potent antitumour immune effector cells (Edin et al, 2013) . In our study, lack of ST2 expression in tumours was associated with a reduction in both macrophage and CD8 þ T cell, and augmented tumour growth. Consistent with a potential antitumorigenic role for ST2, we have shown that a low level of ST2 is associated with poor prognosis and overall survival in human CRC. Thus, our data indicate that the reduction in ST2 expression by tumour cells may result in reduced signalling through ST2, affecting the tumour microenvironment by altering the cell composition of the microenvironment, favouring increased tumour growth.
Recent studies investigating the role of IL-33/ST2 in colon cancer have shown somewhat divergent effects Cui et al, 2015; Maywald et al, 2015) . In contrast to our findings, these studies reported an increase in IL-33 in CRC as compared with adjacent normal tissue and healthy volunteers, with IL-33 having a protective antitumorigenic effect in CRC . Interestingly, the level of IL-33 varied greatly between the studies. Similar to our findings, the level of IL-33 seen in CRC was low in two studies Cui et al, 2015) , with only Maywald et al (2015) reporting high levels of IL-33 in tumours. However, all patients in this study were a heavily pre-treated cohort, receiving 5-fluorouracil-based chemotherapy before analysis. As IL-33 is well known to be released upon cellular damage, it is possible that the chemotherapeutic regimes directly affected the levels of IL-33 in these patients. Indeed, the low level of IL-33 seen in our study may be reflective of the lack of prior chemotherapy in our cohorts. Total ST2 was also reported to be increased in CRC cells relative to adjacent normal cells, in contrast to our findings . These differences could be because of the isoforms of ST2 examined, given that our observed decrease in expression of ST2 was confined to the transmembrane-bound signalling active L-isoform (ST2L). Indeed, to the best of our knowledge, no other study has specifically examined the expression of ST2L in CRC.
Here we have shown that ST2L expression is upregulated by pro-inflammatory stimuli that have been implicated in colon cancer (LPS, TNFa and PGE 2 ), whereas IL-33 appears to be more tightly regulated. This lack of upregulation of IL-33 may well reflect the overall low levels of IL-33 seen in CRC tumour cells. Further characterisation of the function of IL-33 in colon cancer cells revealed that IL-33 did not increase cell proliferation or invasion in vitro, but did induce cell migration. This ability of IL-33 to induce cell migration in vitro suggests that IL-33 may be involved in metastasis in vivo, as suggested by Liu et al (2014) . However, we only observed robust migration of colon cancer cells at higher doses of IL-33, which may not be physiologically relevant. Indeed, IL-33 in the serum of cancer patients, as seen both in this study, and others, was typically in the low pg ml À 1 concentration (Sun et al, 2011; Zhang et al, 2012) .
We also comprehensively characterised induction of cytokine and chemokines by IL-33. Interleukin-33 only induced the expression of CCL2 in human cells, with VEGF and CXCL-1 also being induced in murine cancer cells. Other studies investigating induction of cytokines and chemokines in non-haematopoietic cells have also shown a similar lack of induction of cytokines/ chemokines by IL-33 (Masamune et al, 2010) . This implies that the response of non-haematopoietic cells to IL-33 stimulation is highly restricted. Indeed, this lack of upregulation of inflammatory cytokines and chemokines is perhaps unsurprising, given the role of IL-33 in maintaining barrier function and homeostasis in the gastrointestinal tract (Lopetuso et al, 2012) .
In conclusion, our study has shown a potential antitumorigenic role for ST2L in colon cancer. This is likely mediated by alterations in immune infiltrating cells, in particular through alterations in infiltration by macrophages and CD8 þ T cells. Therefore, targeting ST2L may have potential therapeutic benefit for the treatment of colon cancer. However, given that IL-33 and ST2 appear to have differing and opposing functions, depending on the cell type, tissue and organ examined, further work on the role of IL-33 and ST2 in cancer is required.
